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Abstract
Gram positive (G+) infections make up ,50% of all acute lung injury cases which are characterized by extensive permeability
edema secondary to disruption of endothelial cell (EC) barrier integrity. A primary cause of increased permeability are
cholesterol-dependent cytolysins (CDCs) of G+-bacteria, such as pneumolysin (PLY) and listeriolysin-O (LLO) which create
plasma membrane pores, promoting Ca2+-influx and activation of PKCa. In human lung microvascular endothelial cells
(HLMVEC), pretreatment with the nitric oxide synthase (NOS) inhibitor, ETU reduced the ability of LLO to increase
microvascular cell permeability suggesting an endothelial nitric oxide synthase (eNOS)-dependent mechanism. LLO
stimulated superoxide production from HLMVEC and this was prevented by silencing PKCa or NOS inhibition suggesting a
link between these pathways. Both LLO and PLY stimulated eNOS T495 phosphorylation in a PKC-dependent manner.
Expression of a phosphomimetic T495D eNOS (human isoform) resulted in increased superoxide and diminished nitric oxide
(NO) production. Transduction of HLMVEC with an active form of PKCa resulted in the robust phosphorylation of T495 and
increased peroxynitrite production, indicative of eNOS uncoupling. To determine the mechanisms underlying eNOS
uncoupling, HLMVEC were stimulated with LLO and the amount of hsp90 and caveolin-1 bound to eNOS determined. LLO
stimulated the dissociation of hsp90, and in particular, caveolin-1 from eNOS. Both hsp90 and caveolin-1 have been shown
to influence eNOS uncoupling and a peptide mimicking the scaffolding domain of caveolin-1 blocked the ability of PKCa to
stimulate eNOS-derived superoxide. Collectively, these results suggest that the G+ pore-forming toxins promote increased
EC permeability via activation of PKCa, phosphorylation of eNOS-T495, loss of hsp90 and caveolin-1 binding which
collectively promote eNOS uncoupling and the production of barrier disruptive superoxide.
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Introduction
Gram positive (G+) infections make up ,50% of acute
respiratory distress syndrome (ARDS) cases and Streptococcus
pneumoniae infections account for 45% of all community-acquired
pneumonia (CAP) cases. In individuals over 50 years of age, there
are over 500,000 yearly cases of non-bacteremic pneumococcal
pneumonia and over 25,000 pneumococcal-related deaths that
result in a health care burden exceeding $5 billion dollars[1].
Despite considerable investigation, there are currently no effective
therapeutics for ARDS- and CAP- related pulmonary barrier
dysfunction. These facts provide a strong rationale for more
intensive research into the molecular mechanisms of endothelial
barrier regulation.
CAP is accompanied by extensive permeability edema, charac-
terized by a disruption in endothelial cell (EC) barrier integrity [2].
Despite the extensive use of potent antibiotics and aggressive
intensive-care support, the mortality rate in CAP remains
unacceptably high [3]. A major complication with these infections
is the endothelial cytotoxicity and edema induced by bacterial
virulence factors. Pneumolysin (PLY, S. pneumoniae) as well as its
family member listeriolysin-O (LLO, Listeria monocytogenes) are
members of the family of cholesterol-dependent pore-forming
cytolysins (CDCs) [4] and are released from G+ bacteria upon cell
lysis. Bactericidal antibiotics can promote significant release of G+-
toxins and cause extensive and enduring injury even in a sterile
lung. These thiol-sensitive gram positive (G+) virulence factors
oligomerize in the presence of cholesterol to form plasma
membrane pores that not only stimulate calcium entry in various
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cell types but also stimulate phospholipase C and protein kinase C
alpha (PKCa) as we and others have recently shown [5–7]. Listeria
infections are most commonly associated with food-borne diseases
but can result in severe and often fatal pulmonary diseases that are
also characterized by permeability edema [8]. Despite the greater
appreciation of the importance of G+ toxins, the mechanisms by
which PLY and LLO induce endothelial barrier disruption are
poorly understood.
The liberation of nitric oxide (NO) from the vascular
endothelium has been well established as an important regulator
of the permeability of the microcirculation. In the lung, numerous
studies have shown that endothelial nitric oxide synthase (eNOS) is
barrier protective [9,10]. However, others have shown a
facilitative role for eNOS in the actions of edemagenic agents
and in eNOS knockout mice the ability of VEGF to induce
microvascular permeability is reduced [11]. These disparate
findings suggest that eNOS can have multiple roles in the
regulation of endothelial permeability and this is influenced by the
amount of NO, vascular bed and agonist [12]. The role of eNOS
in the loss of endothelial barrier function in response to G+ toxins
is poorly defined and a goal of the current study.
The activity of eNOS is strongly influenced by a number of
post-translational mechanisms including protein phosphorylation
[13]. eNOS is phosphorylated on at least 7 sites and serine
residues, S615, S633 and S1177 (human isoform) lie within the
two major auto-inhibitory domains of the C-terminus of eNOS
and work collectively to increase enzyme activity [14]. In contrast
to the positive regulatory phosphorylation sites, eNOS is
negatively regulated by the phosphorylation of Threonine 495
(T495) [15–17] and endothelial agonists that activate eNOS
induce the dephosphorylation of this site [15–17]. Increased
phosphorylation of T495 (P-T495) is stimulated by activators of
protein kinase C such as PMA and is prevented by inhibitors of
conventional protein kinase C isoforms [15,17]. The mechanism
by which P-T495 modifies eNOS activity is not fully understood
and studies using phospho-mutants of eNOS have shown that the
P-T495 can ‘‘uncouple’’ eNOS, reducing the synthesis of NO and
increasing superoxide production [18]. The production of
superoxide from eNOS reduces NO-dependent signaling in two
ways. Firstly, increased superoxide production comes at the
expense of NO synthesis and secondly, superoxide interacts avidly
with NO in a diffusion limited reaction to form peroxynitrite [27].
Peroxynitrite is a potent oxidant and has biological effects that are
distinct from that of NO (nitration versus S-nitrosylation). The role
of eNOS phosphorylation or uncoupling in response to G+ toxins
is not resolved.
Protein: protein interactions have also been well documented in
their ability to regulate eNOS activity. Hsp90 is a molecular
chaperone that binds to numerous client proteins and regulates
protein folding and post-translational activity [19]. The binding of
hsp90 to eNOS has been shown to facilitate NO production and
regulate the fidelity of eNOS synthesis whereby a loss of hsp90
binding can promote the increased synthesis of superoxide [20,21].
Caveolin-1 is another well characterized protein that dynamically
interacts with eNOS [22–24]. In contrast to hsp90, caveolin-1 is a
negative regulator of eNOS activity but it does share a recently
discovered ability to influence eNOS fidelity by sequestering and
inhibiting uncoupled enzyme [25]. The ability of G+ toxin-to
regulate eNOS phosphorylation and protein: protein interactions
has not been studied. Therefore, the goal of this study was to
elucidate the mechanisms by which the G+ toxins alter endothelial
barrier integrity with a focus on the regulation of eNOS
phosphorylation, protein: protein interactions and enzyme fidelity.
Materials and Methods
Cell culture
HLMVEC were isolated and cultured in-house as described
previously [26] or from commercial sources (Lonza) and grown in
Endothelial Growth Medium-2-Microvessel (EGM-2MV) consist-
ing of defined growth factors and supplemented with additional
FBS up to 5% final concentration (Lonza). Cells were grown at 37
uC in 5% CO2 incubator and used from passage 2–8. COS-7 cells
were cultured in Dulbecco’s modified Eagle’s medium (Invitrogen,
Carlsbad, CA) containing L-glutamine, penicillin, streptomycin,
and 10% (v/v) fetal bovine serum. Cells were transfected using
Lipofectamine 2000 reagent (Invitrogen) as described previous-
ly[27].).
Antibodies and reagents
Antibodies against phosphorylated PKC substrates, eNOS P-
T495, eNOS P-S1177, PKCa were purchased from Cell
Signaling. GAPDH (Santa Cruz) and eNOS, hsp90 and
caveolin-1 were obtained from BD biosciences. S-ethylisothiourea
(ETU) and Gö 6976 were obtained from Sigma-Aldrich.
Bacterial toxins
LPS-free LLO and PLY were expressed and purified from the
wild type L. innocua 6a strain, as described previously[5,28].
Endothelial permeability
Measurements of trans-endothelial resistance (TER) in
HLMVEC, an index of changes in permeability [29], were
performed as described previously [30]. Approximately 60,000
cells were seeded per well in a 8W10E array. Media was changed
at 24h and again to serum free media at 48h, prior to the addition
of G+ toxins. Resistance was measured using the ECIS Zh model
and normalized to each well’s value at 0h.Toxins were applied
when the resistance was stable between 1000-1300 ohms at a
frequency of 4000Hz and the capacitance was between 22-29
nanofarads. Cells were preincubated with ETU or Gö 6976 for
0.5h prior to the addition of toxins.
Co-immunoprecipitation and Western blotting analysis
Cells were lysed on ice in 20 mM Tris-HCl (pH 7.4), 1% Triton
X-100, 100 mM NaCl, 1 mM Na3VO4, 10 mM NaF, and 1%
protease inhibitor cocktail (Sigma). Soluble extracts were incubat-
ed for 2 h at 4uC with relevant antibodies: anti-eNOS (BD
Biosciences) and a negative isotype control mouse immunoglobulin
(IgG) (Santa Cruz Biotechnology), and complexes precipitated
with protein A/G agarose (Santa Cruz Biotechnology). Western
blotting was performed as described previously using anti-
GAPDH, eNOS, P-T495 eNOS, P-1177 eNOS, phosphorylated
PKC substrate, hsp90 and caveolin-1.
Transient knockdown of PKC gene with siRNA
The siRNA targeting PKCa (siRNA ID: s11094) was obtained
from Applied Biosystems. Validated control and targeting siRNA
were transfected into HLMVEC using siPORTTM Amine
(Applied Biosystems).
Measurement of Nitric Oxide and Peroxynitrite
The accumulation of nitrite in the medium was measured by
NO-specific chemiluminescence (Ionics). Background levels of
nitrite in control transfected cells were subtracted. The formation
of ONOO- was determined by the ONOO2-dependent oxidation
of dihydrorhodamine (DHR) 123 to rhodamine 123 as we have
Mechanisms of G+-Toxin Induced Barrier Dysfunction
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previously described [31]. Transfected cells were replated onto
black tissue culture-treated 96-well plates (Thermo Fisher Scien-
tific) at a density of 5 6104 cells/well. Medium 200 (phenol red-
free) was added containing 5 mmol/L DHR 123. After 60-min
incubation at 37uC, the fluorescence of rhodamine 123 was
measured by excitation 485 nm, emission 545 nm using a
POLARstar reader. Results are expressed as % DHR oxidation
compared to control transfected cells.
Measurement of Superoxide
Superoxide generation in intact cells was measured using
electron paramagnetic resonance (EPR) measurements as de-
scribed previously using the spin probe 1-hydroxy-3-methoxycar-
bonyl-2,2,5,5-tetramethylpyrrolidine?HCl (CMH; Alexis Bio-
chemicals)[32]. HLMVEC were incubated with 20 ml of spin-
trap stock solution consisting of CMH [20 mM in Dulbecco’s PBS
(DPBS) plus 25 mM desferrioxamine (Calbiochem) and 5 mM
diethyldithiocarbamate (Alexis Biochemicals)] prior to addition of
G+ toxins for 45-min at 37uC. Cells were then detached and
pelleted by centrifugation (500 6 g). The cell pellet was washed
and suspended in a final volume of 35 ml of DPBS, loaded into a
50-ml capillary tube, and analyzed with a MiniScope MS200 EPR
(Magnettech, Berlin, Germany) at a microwave power of 40 mW
(modulation amplitude of 3,000 mG, and modulation frequency of
100 kHz). The amplitude of EPR spectra were measured using
ANALYSIS software (version 2.02; Magnettech).
Statistical analysis
Data were reported as mean 6 SE and statistical analyses
performed using Instat software (GraphPad Software Inc., San
Diego, CA) with a two-tailed student’s t-test or ANOVA with a
post-hoc test where appropriate. Differences were considered as
significant at p , 0.05.
Results
The ability of G+-toxins to disrupt endothelial
permeability is dependent on PKC and NO signaling
HLMVEC were cultured to confluence on integrated gold-
plated electrodes and transendothelial electrical resistance (TER)
monitored until a stable plateau was attained. Cells were then
pretreated with inhibitors of nitric oxide synthase (ETU [33],
100 mM, 30 mins) or protein kinase C (Gö 6976, 10 mM, 30 mins).
Following the reacquisition of a stable baseline, the G+ positive
toxin, LLO (250 ng/ml) was administered in serum free media
and decreases in TER are reflective of increased permeability of
the endothelial cell monolayer [29]. In cells pretreated with ETU
or Gö 6976 there was a significant reduction in the ability of LLO
to disrupt the endothelial barrier (Figure1A-B) suggesting
functional roles for PKC and endothelial nitric oxide synthase
(eNOS) in the ability of G+ toxins to disrupt the endothelial
barrier.
G+-toxins induce superoxide release from HLMVEC in a
PKC and NOS-dependent manner
Confluent HLMVECs were stimulated with LLO (250 ng/ml)
and superoxide levels measured using EPR with the spin probe
CMH. LLO induced the release of superoxide from HLMVEC
and this ability was absent in cells pretreated with the NOS
inhibitor (ETU, 100 mM) (Figure 2A–B). We next investigated
the role of PKCa in HLMVEC transfected with either control
siRNA (validated commercial control siRNA that does not target
mammalian genes) or siRNA to PKCa. The ability of LLO
(250 ng/ml) to promote superoxide release was significantly
reduced in cells in which PKCa was silenced (Figure 2C–D)
indicating that the ability of G+ toxins to induce superoxide release
is dependent on both PKCa and eNOS.
G+-toxins stimulate PKCa and eNOS T495
phosphorylation
Confluent HLMVEC were pretreated with the PKC inhibitor
Gö6976 and then exposed to LLO or PLY for 30 min. Cells were
lysed and Westerns blots performed using antibodies that
recognize the increased phosphorylation of PKC substrates as a
measure of PKC activity. Both LLO and PLY increased the
phosphorylation of PKC-substrates and this was significantly
decreased by the PKC inhibitor Go6976 (Figure 3A–B). In
parallel experiments, we next assessed the ability of LLO and PLY
to increase the phosphorylation of eNOS at T495, a known PKCa
phosphorylation site [17]. Using a selective eNOS T495
phosphorylation state specific antibody, we found that both LLO
and PLY significantly increased eNOS phosphorylation at T495
and this effect was blunted in cells pre-treated with the PKC
inhibitor (Figure 3C–D). There was no significant change in the
basal phosphorylation of eNOS T-495 in the presence of Go6976
(Figure 3E). We next used a genetic approach to selectively
silence PKCa in HLMVEC. HLMVEC were transfected with
human specific PKCa siRNA or a validated control siRNA (as
shown in Figure 2D). Cells were stimulated with PLY and
immunoblotted for PKCa, phosphorylated PKC substrates, eNOS
phosphorylated at T495, total eNOS and a loading control,
GAPDH. The ability of PLY to promote increased PKC activity
and eNOS T-495 phosphorylation was significantly blunted in
cells where PKCa was silenced (Figure 4A–D). To verify that
eNOS is a bonafide direct substrate for PKCa, we performed an in
vitro kinase reaction using recombinant PKCa and affinity (ADP-
sepharose) purified eNOS. We found that in the presence of ATP,
eNOS was robustly phosphorylated by PKCa as determined by
the relative levels of phosphorylated P-T495 eNOS to total eNOS
(Figure 4E).
Phosphorylation of T495 eNOS promotes uncoupling
To ascertain the functional consequences of phosphorylation of
T495 on eNOS, we expressed aT495D phosphomimetic form of
eNOS in COS-7 cells and measured the production of superoxide
via EPR and the production of NO using NO-specific chemilu-
minescence relative to that from the wild type (WT) enzyme. The
eNOS T495D phosphomimetic produced significantly higher
amounts of superoxide and reduced amounts of NO compared to
the WT enzyme at equal levels of expression (Figure 5A, B). To
determine whether the increased phosphorylation of T495 on
eNOS can result in enzyme uncoupling we co-transfected eNOS
with an active form of PKCa. The co-expression of WT-eNOS
and myr-PKCa resulted in robustly increased eNOS P-T495
whereas S1179 phosphorylation was unchanged (Figure 5C,
lower panels). The phosphorylation of T495 was associated with
increased peroxynitrite production as measured using DHR
fluorescence (Figure 5C, upper graph) and a quantitative dot
blot for 3-nitrotyrosine (Figure 5D).
G+-toxins promote the dissociation of hsp90 and
caveolin-1 from eNOS
To determine the mechanism by which G+-toxins elicit eNOS
uncoupling we monitored the relative binding of the eNOS
associated proteins, hsp90 and caveolin-1. Both proteins have been
shown to influence superoxide production from eNOS [21,25] and
Mechanisms of G+-Toxin Induced Barrier Dysfunction
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it is not yet known whether G+-toxins influence their binding to
eNOS. The addition of LLO to HLMVEC did not decrease the
total cellular levels of eNOS, hsp90 or caveolin-1 (Figure 6A). To
ascertain whether LLO impacts the relative binding of caveolin-1
and hsp90 to eNOS, eNOS was immunoprecipitated and the
levels of bound hsp90 and caveolin-1 determined by Western
blotting. We found that LLO induced a significant decrease in the
association of eNOS with hsp90 and in particular caveolin-1
(Figure 6B-D). We next investigated whether the loss of caveolin-
1-binding can impact the ability of PKCa to induce superoxide
production from eNOS. COS-7 cells were transfected with eNOS
and either a control plasmid (RFP) or eNOS and a constitutively
active PKCa as shown in Figure. 5C and eNOS purified by
affinity chromatography. In vitro superoxide production from
purified eNOS was monitored by EPR in the presence of
calmodulin, calcium and NADPH with and without the
caveolin-1 scaffolding domain peptide. The production of
superoxide from eNOS that was co-expressed with the active
Figure 1. Inhibition of either eNOS or Protein Kinase C (PKC) ameliorates endothelial barrier disruption to G+-toxins. Confluent
human lung microvascular endothelial cells (HLMVEC) were pretreated with and without (A) the PKCa inhibitor, Go6976 (1 mM,) or (B) the NOS
inhibitor (ETU, 100 mM) and stimulated with the Gram positive bacterial (G+) toxin, listeriolysin (LLO, 250ng/ml). Changes in trans-endothelial
resistance (TER) were recorded over time. (n = 6),* p,0.05 versus control, # p,0.05 versus ETU or Go6976.
doi:10.1371/journal.pone.0099823.g001
Figure 2. G+ -bacterial toxins stimulate endothelial superoxide production. HLMVEC were exposed to LLO (250 ng/ml, 30 min) in (A) the
presence and absence of ETU (100 mM, representative trace shown in the upper panel, quantification in the lower panel) or (B) HLMVEC transfected
with control or PKCa siRNA (60 nM). Superoxide was detected using the CMH (20 mM) spin probe and EPR. PKCa expression relative to GAPDH in
HLMVEC lysates was determined by Western blot. n = 4–5. * p,0.05 versus control
doi:10.1371/journal.pone.0099823.g002
Mechanisms of G+-Toxin Induced Barrier Dysfunction
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form of PKCa was greater than eNOS alone and the PKCa-
stimulated increase in superoxide production was reversed by co-
incubation with the caveolin-1 peptide (Figure 6E).
Collectively, these data suggest that LLO and PLY stimulate
eNOS uncoupling in HLMVEC via the activation of PKCa.
Active PKCa stimulates the phosphorylation of eNOS at T495
and together with reduced caveolin-1 and hsp90 binding this leads
to a reduction in enzyme fidelity resulting in greater production of
superoxide and peroxynitrite and a corresponding decrease in the
levels of barrier protective NO (Figure 7).
Discussion
Previous studies have shown that disruption of the pulmonary
endothelial barrier to the G+-toxins, LLO and PLY involves the
activation of PKC [5,6]. The goal of the current study was to
identify the downstream mechanisms by which PKC promotes
disruption of the microvascular endothelial barrier. In HLMVEC
we found that an inhibitor of nitric oxide synthases prevented the
ability of G+-toxins to decrease transendothelial resistance,
suggesting that eNOS was a crucial mediator of barrier
dysfunction. Given that NO is generally considered to be barrier
protective [10,34-36], we investigated whether G+ toxins promote
the synthesis of superoxide, which can also be produced from
uncoupled eNOS. We found that the G+ -toxin, LLO promoted
the PKCa and NOS-dependent production of superoxide.
Subsequent studies revealed that the PKC and eNOS-dependent
production of superoxide is connected by the ability of LLO/PLY
to promote the PKC-dependent phosphorylation of eNOS at
Figure 3. G+ -bacterial toxins stimulate the phosphorylation of PKC substrates and eNOS at T495. HLMVEC cells were pretreated with or
without the PKCa inhibitor (Go6976, 1 mM) and stimulated with listeriolysin (LLO, 60 ng/ml) or pneumolysin (PLY, 30 ng/ml) for 30 min. The
phosphorylation of (A–B) PKC substrates and (C–D) eNOS at T495 was determined using phosphorylation state specific antibodies. (n = 5). * p,0.05.
doi:10.1371/journal.pone.0099823.g003
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T495. To determine whether the phosphorylation of T495 can
account for the increased superoxide production from eNOS we
expressed the phosphomimetic T495D eNOS. Compared to the
WT enzyme, the T495D eNOS produced more superoxide and
less NO at equal levels of expression. Furthermore, an active form
of PKCa stimulated the phosphorylation of T495 on eNOS and
increased the production of peroxynitrite which is formed by the
interaction of NO with superoxide. Lastly, LLO stimulated the
dissociation of caveolin-1 and hsp90 from eNOS, events that have
been shown to increase eNOS-derived superoxide [21,25]. This
mechanism was confirmed using an in vitro assay where affinity
purified eNOS co-expressed with active PKCa produced more
superoxide than the WT enzyme alone and the ability of a
caveolin-1 scaffolding domain peptide to reverse the excess
production of superoxide from eNOS co-expressed with PKCa.
Overall our results support the ability of G+ toxins to disrupt the
integrity of the HLMVEC barrier via the activation of PKCa,
phosphorylation of T495 eNOS, loss of caveolin-1 and hsp90
binding and disruption of the NO/superoxide balance favoring
the increased production of superoxide.
Figure 4. G+ -bacterial toxins utilize PKCa to stimulate eNOS T-495 phosphorylation. (A) HLMVEC were transfected with control or PKCa
specific siRNA (60 nM), stimulated with PLY (30 ng/ml, 30 min.) the relative degree PKCa, phosphorylated PKC substrates, phosphorylated eNOS
T495, total eNOS and GAPDH determined by Western blot. (B) Relative densitometry of PKCa relative to GAPDH, (C) phosphorylated PKC substrates
(D) phosphorylated eNOS T495 relative to total eNOS. (E) In vitro kinase assay showing the ability of active recombinant PKCa to directly
phosphorylate affinity purified human eNOS at T495. (n = 2–5). * p,0.05 versus control.
doi:10.1371/journal.pone.0099823.g004
Mechanisms of G+-Toxin Induced Barrier Dysfunction
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The ability of NOS inhibitors to protect against G+-toxin
induced barrier disruption was a surprising observation. The
consensus view is that eNOS-derived NO and exogenous NO
protects against increased endothelial permeability in response to a
number of agents including thrombin [34], hyperoxia [36],
oxidants [37], PMA [38] and TxA2 [39] and also has an
important role in maintaining barrier function under basal
conditions [10]. In contrast, reactive oxygen species have been
shown to promote disruption of the endothelial barrier [40-42].
However, it is less well appreciated that nitric oxide synthase
inhibitors can protect against barrier disruption in response to
stimuli that are known to promote superoxide production [43] and
also that oxidants and reactive nitrogen species such as peroxyni-
trite can directly promote endothelial barrier dysfunction[44].
Recent evidence suggests that under the appropriate conditions
and with certain stimuli, eNOS can produce increased amounts of
superoxide and peroxynitrite at the expense of nitric oxide in a
process termed eNOS uncoupling [45,46].
It has previously been shown that G+-toxins induce superoxide
production in neutrophils that express the NADPH oxidase, Nox2
[47] but whether G+-toxins stimulate superoxide from HLMVEC
has not yet been studied. We found that LLO stimulated
superoxide production in HLMVEC that was both PKCa and
eNOS-dependent. The ability of PKCa to promote eNOS T495
phosphorylation suggested a possible mechanism for eNOS
uncoupling. Previous studies have suggested that phosphorylation
of eNOS at T495 can compromise enzyme fidelity [18].
Consistent with this, we found that a phosphomimetic T495D
eNOS produces greater superoxide and reduced NO and that
activation of PKCa can drive eNOS T495 phosphorylation and
Figure 5. The PKCa-dependent phosphorylation of eNOS at T495 results in increased superoxide production. (A) Superoxide release
as determined by EPR and (B) nitric oxide release measured by NO-specific chemiluminescence from COS-7 cells transfected with WT eNOS or the
T495D phosphomimetic. The level of eNOS in transfected cells was determined by Western blot (lower panels). (C) Upper graph, relative production
of peroxynitrite (ONOO-) as determined by DHR fluorescence in COS-7 cells co-transfected with WT eNOS with and without an active form of PKCa
(myr-PKCa). Lower panels, the relative expression of phosphorylation of eNOS at T495 and S1179, total eNOS, expression of V5-tagged myr-PKCa and
GAPDH as determined by Western blotting. n = 4–5. * p,0.05 versus control/WT.
doi:10.1371/journal.pone.0099823.g005
Mechanisms of G+-Toxin Induced Barrier Dysfunction
PLOS ONE | www.plosone.org 7 July 2014 | Volume 9 | Issue 7 | e99823
the increased formation of peroxynitrite. In contrast, Chen et al.
showed that the direct in vitro phosphorylation of recombinant
eNOS at T495 by PKCa does not result in increased superoxide
production [48]. Reconciling these seemingly disparate findings
are studies showing that changes in protein: protein interactions
can influence eNOS fidelity and superoxide production. For
Figure 6. Gram+ toxin induced dissociation of caveolin-1 mediates the increase in eNOS-derived superoxide production. HLMVEC
were treated with or without LLO (250 ng/ml, 30 min.) and (A) total levels of eNOS, hsp90 and caveolin-1(cav-1) determined by Western blot in cell
lysates. (B) Lysates were subject to immunoprecipitation using either non-immune IgG or anti-eNOS and immune complexes immunoblotted for
eNOS and associated hsp90 and caveolin-1. Relative densitometry of (C) hsp90 bound to eNOS or (D) caveolin-1 bound to eNOS. (E) In vitro
superoxide production from eNOS affinity purified from COS-7 cells co-transfected with eNOS or eNOS with the active form of PKCa (myr-PKCa) in the
presence and absence of the caveolin-1 scaffolding domain mimicking peptide (10 mM). n = 4–6. * p , 0.05
doi:10.1371/journal.pone.0099823.g006
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example, Pritchard et al. showed that inhibition of the N-terminal
ATP-dependent, protein folding activity of hsp90 and the
subsequent loss of hsp90 binding to eNOS results in eNOS
uncoupling and increased superoxide production [21]. More
recently, Karrupiah et al. have shown that caveolin-1 binds
preferentially to biopterin-deficient eNOS and reduces the amount
of superoxide produced from uncoupled eNOS [25]. In the
current study, we found that G+ toxins promote decreased hsp90,
and in particular, caveolin-1 binding to eNOS. The ability of
calcium-mobilizing agonists to promote the dissociation of eNOS
and caveolin-1 has been shown by others [22,23,49]. It should also
be noted that PLY, apart from directly affecting NO generation by
eNOS, can also indirectly affect eNOS function, i. e. by means of
increasing the activity of the eNOS competitor arginase 1[5].
Both LLO and PLY are pore forming toxins that stimulate
calcium entry [5,28,47,50,51] and thus it is likely that elevation of
intracellular calcium and enhanced calcium/calmodulin-binding
to eNOS contributes to the ability of G+ toxins to promote the
dissociation of caveolin-1. To determine whether loss of these
proteins mediates the reduction in eNOS fidelity and increased
superoxide production, we measured superoxide production from
eNOS in an in vitro NOS activity assay in the presence and absence
of a caveolin-1 peptide. The caveolin-1 peptide mimics the region
of caveolin-1 that binds to eNOS [24,52] and completely reversed
the increased production of superoxide from eNOS activated by
PKCa, which is consistent with the findings of other studies
[25,48]. Other studies have shown that microvascular permeabil-
ity is increased in caveolin-1 knockout mice along with increased
peroxynitrite and protein nitration and that these effects can be
reversed with inhibition of eNOS and antioxidants[53–55].
Collectively, these results suggest that the loss of eNOS fidelity,
mediated at least in part by decreased caveolin-1 binding, can
promote increased endothelial permeability.
While our study supports a role for PKCa in the phosphory-
lation of eNOS on T495, it should be noted that other PKC
isoforms and kinases can influence the phosphorylation of this site
and this may be dependent on the cell type and stimulus. The
phosphorylation of eNOS at T495 can be mediated by other PKC
isoforms including PKCb [56] and PKCd [57] as well as other
kinases such as AMPK [58] and Rho kinase [59]. It is not yet
known whether LLO or PLY employ other PKC isoforms or
kinases to induce endothelial barrier disruption. However, our
data suggests that silencing PKCa alone is sufficient to suppress
stimulated increases in superoxide and eNOS T495 phosphory-
lation. The mechanisms by which PLY and LLO activate PKCa
are not fully elucidated. The ability of G+ pore forming toxins to
mobilize calcium is well established [5,28,47,50] and lanthanum
chloride, an a specific inhibitor of calcium entry has been shown to
reduce the barrier-disruptive effects of PLY in HLMVEC. G+ pore
forming toxins, however, do not act strictly as calcium ionophores
and have been shown to stimulate numerous signaling pathways
including phospholipase PLA2 [60] and PLC [47]. PLY is known
to bind to cell membranes in a cholesterol dependent manner that
induces significant deformation of the membrane and a diverse
population of transmembrane pores of different sizes and ion
conductivity [61,62]. Others have shown that PLY binding can
promote the destabilization of membranes leading to aggregated
vesicles and fusion of liposomes[63]. How this influences PLC and
PKCa activity is not yet known but it is likely that the combination
of altered membrane signaling in combination with robust calcium
entry is sufficient to activate PKCa. The relative ability of the
PKC inhibitor to protect against G+-toxin induced barrier
disruption was much greater than the protection afforded by
suppression of eNOS suggesting the possibility that additional
mechanisms contribute to barrier disruption. In addition to eNOS,
NADPH oxidases have been shown to be downstream targets of
PKC [64–66]. It remains possible, and even likely, that NADPH
oxidase isoforms in the vascular endothelium may be activated by
PKCa in response to G+-toxins. This possibility will be explored in
future studies.
Currently there are no established therapies for permeability
edema associated with infection from G+- bacteria. Therefore a
greater understanding of the mechanisms by which the G+-toxins,
PLY and LLO evoke increases in microvascular permeability is a
vital endeavor in the search for more effective therapeutics. Our
study reveals novel roles for PKCa and eNOS uncoupling and
strategies to prevent the loss of eNOS fidelity such as increasing
caveolin-1 or the production of reactive oxygen species may be of
significant benefit in reducing the morbidity and mortality of G+-
induced pneumonia and pulmonary edema.
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